- Record: found
- Abstract: found
- Article: not found
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Stephen Johnston
1 ,
John Pippen ,
Xavier Pivot ,
Mikhail Lichinitser ,
Saeed Sadeghi ,
Veronique Dieras ,
Henry Leonidas Gomez ,
Gilles Romieu ,
Alexey Manikhas ,
M John Kennedy ,
Michael F Press ,
Julie Maltzman ,
Allison Florance ,
Lisa O'Rourke ,
Cristina Oliva ,
Steven Stein ,
Mark Pegram
Nov 20 2009
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor letrozole as first-line treatment of hormone receptor (HR) -positive metastatic breast cancer (MBC).